These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28899370)

  • 1. Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia.
    Sicras-Mainar A; Navarro-Artieda R; Mora AM; Hernández M
    BMC Urol; 2017 Sep; 17(1):83. PubMed ID: 28899370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands.
    Drake MJ; Bowditch S; Arbe E; Hakimi Z; Guelfucci F; Amri I; Nazir J
    BMC Urol; 2017 May; 17(1):36. PubMed ID: 28532455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia.
    MacDiarmid SA
    Curr Urol Rep; 2008 Jul; 9(4):265-71. PubMed ID: 18765124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms.
    Sarma AV; Wei JT
    N Engl J Med; 2012 Jul; 367(3):248-57. PubMed ID: 22808960
    [No Abstract]   [Full Text] [Related]  

  • 5. Healthcare resource utilization and cost among males with lower urinary tract symptoms with a predominant storage component in Spain: The epidemiological, cross-sectional MERCURY study.
    Errando-Smet C; Müller-Arteaga C; Hernández M; Lenero E; Roset M
    Neurourol Urodyn; 2018 Jan; 37(1):307-315. PubMed ID: 28464366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of benign prostatic hyperplasia.
    Nunes RV; Manzano J; Truzzi JC; Nardi A; Silvinato A; Bernardo WM;
    Rev Assoc Med Bras (1992); 2017 Feb; 63(2):95-99. PubMed ID: 28355368
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis.
    Lenfant L; Pinar U; Roupret M; Mozer P; Chartier-Kastler E; Seisen T
    J Urol; 2023 Feb; 209(2):314-324. PubMed ID: 36395428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
    Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
    J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of lower urinary tract symptoms/benign prostatic hyperplasia: anything new in 2015.
    Schauer I; Madersbacher S
    Curr Opin Urol; 2015 Jan; 25(1):6-11. PubMed ID: 25393269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK.
    Speakman M; Kirby R; Doyle S; Ioannou C
    BJU Int; 2015 Apr; 115(4):508-19. PubMed ID: 24656222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia.
    Dimitropoulos K; Gravas S
    Drug Des Devel Ther; 2015; 9():1707-16. PubMed ID: 25834406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimuscarinics, β-3 Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm.
    Osman NI; Aldamanhori R; Mangera A; Chapple CR
    Urol Clin North Am; 2016 Aug; 43(3):337-49. PubMed ID: 27476126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: A Retrospective Study of Treatment Persistence and Adherence to α-Blocker plus Antimuscarinic Combination Therapies, in Men with LUTS/BPH in the Netherlands.
    Kaplan SA
    J Urol; 2018 Nov; 200(5):919. PubMed ID: 30360295
    [No Abstract]   [Full Text] [Related]  

  • 20. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.